The medium term support area around 66.4 USD should allow Merck & Co., Inc shares to re-establish an upward trend in the short term. Investors have an opportunity to buy the stock and target the $ 77.7.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Merck & Co., Inc accounts for 4.70 % of our USA Portfolio. A trade is currently open since 10/23/2019 with a purchase price of $ 81.81. Discover the other 19 stocks of the USA portfolio managed by the MarketScreener portfolio management team.
The share is getting closer to its long-term support in weekly data, at USD 66.58, which offers good timing for buyers.
Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 66.4 support.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The company's earnings releases usually do not meet expectations.
The company's enterprise value to sales, at 3.79 times its current sales, is high.
The underlying tendency is negative on the weekly chart below the resistance at 79.73 USD
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.